a1 Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA
a2 Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, USA
a3 Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
a4 Alcohol Research Center, VA Connecticut Healthcare System, West Haven, CT, USA
Objective diagnostics of excessive alcohol use are valuable tools in the identification and monitoring of subjects with alcohol use disorders. A number of potential biomarkers of alcohol intake have been proposed, but none have reached widespread clinical usage, often due to limited diagnostic sensitivity and specificity. In order to identify novel potential biomarkers, we performed proteomic biomarker target discovery in plasma samples from non-human primates that chronically self-administer high levels of ethanol. Two-dimensional difference in-gel electrophoresis (2D-DIGE) was used to quantify plasma proteins from within-subject samples collected before exposure to ethanol and after 3 months of excessive ethanol self-administration. Highly abundant plasma proteins were depleted from plasma samples to increase proteomic coverage. Altered plasma levels of serum amyloid A4 (SAA4), retinol-binding protein, inter-alpha inhibitor H4, clusterin, and fibronectin, identified by 2D-DIGE analysis, were confirmed in unmanipulated, whole plasma from these animals by immunoblotting. Examination of these target plasma proteins in human subjects with excessive alcohol consumption (and control subjects) revealed increased levels of SAA4 and clusterin and decreased levels of fibronectin compared to controls. These proteins not only serve as targets for further development as biomarker candidates or components of biomarker panels, but also add to the growing understanding of dysregulated immune function and lipoprotein metabolism with chronic, excessive alcohol consumption.
(Received October 28 2010)
(Reviewed December 14 2010)
(Revised December 22 2010)
(Accepted December 29 2010)
(Online publication February 08 2011)
c1 Address for correspondence: K. E. Vrana, Ph.D., Department of Pharmacology, Penn State College of Medicine, R130, 500 University Drive, Hershey, PA 17033-0850, USA. Tel.: 717-531-8285 Fax: 717-531-0419 Email: email@example.com
* The first two authors contributed equally to this work.
† The final two authors contributed equally to this work.